Base de dados : MEDLINE
Pesquisa : D26.650 [Categoria DeCS]
Referências encontradas : 2120 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 212 ir para página                         

  1 / 2120 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28639707
[Au] Autor:Westby MJ; Dumville JC; Soares MO; Stubbs N; Norman G
[Ad] Endereço:Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester Academic Health Science Centre, Jean McFarlane Building, Oxford Road, Manchester, UK, M13 9PL.
[Ti] Título:Dressings and topical agents for treating pressure ulcers.
[So] Source:Cochrane Database Syst Rev;6:CD011947, 2017 06 22.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both. Dressings are widely used to treat pressure ulcers and promote healing, and there are many options to choose from including alginate, hydrocolloid and protease-modulating dressings. Topical agents have also been used as alternatives to dressings in order to promote healing.A clear and current overview of all the evidence is required to facilitate decision-making regarding the use of dressings or topical agents for the treatment of pressure ulcers. Such a review would ideally help people with pressure ulcers and health professionals assess the best treatment options. This review is a network meta-analysis (NMA) which assesses the probability of complete ulcer healing associated with alternative dressings and topical agents. OBJECTIVES: To assess the effects of dressings and topical agents for healing pressure ulcers in any care setting. We aimed to examine this evidence base as a whole, determining probabilities that each treatment is the best, with full assessment of uncertainty and evidence quality. SEARCH METHODS: In July 2016 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses, guidelines and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. SELECTION CRITERIA: Published or unpublished randomised controlled trials (RCTs) comparing the effects of at least one of the following interventions with any other intervention in the treatment of pressure ulcers (Stage 2 or above): any dressing, or any topical agent applied directly to an open pressure ulcer and left in situ. We excluded from this review dressings attached to external devices such as negative pressure wound therapies, skin grafts, growth factor treatments, platelet gels and larval therapy. DATA COLLECTION AND ANALYSIS: Two review authors independently performed study selection, risk of bias assessment and data extraction. We conducted network meta-analysis using frequentist mega-regression methods for the efficacy outcome, probability of complete healing. We modelled the relative effectiveness of any two treatments as a function of each treatment relative to the reference treatment (saline gauze). We assumed that treatment effects were similar within dressings classes (e.g. hydrocolloid, foam). We present estimates of effect with their 95% confidence intervals for individual treatments compared with every other, and we report ranking probabilities for each intervention (probability of being the best, second best, etc treatment). We assessed the certainty (quality) of the body of evidence using GRADE for each network comparison and for the network as whole. MAIN RESULTS: We included 51 studies (2947 participants) in this review and carried out NMA in a network of linked interventions for the sole outcome of probability of complete healing. The network included 21 different interventions (13 dressings, 6 topical agents and 2 supplementary linking interventions) and was informed by 39 studies in 2127 participants, of whom 783 had completely healed wounds.We judged the network to be sparse: overall, there were relatively few participants, with few events, both for the number of interventions and the number of mixed treatment contrasts; most studies were small or very small. The consequence of this sparseness is high imprecision in the evidence, and this, coupled with the (mainly) high risk of bias in the studies informing the network, means that we judged the vast majority of the evidence to be of low or very low certainty. We have no confidence in the findings regarding the rank order of interventions in this review (very low-certainty evidence), but we report here a summary of results for some comparisons of interventions compared with saline gauze. We present here only the findings from evidence which we did not consider to be very low certainty, but these reported results should still be interpreted in the context of the very low certainty of the network as a whole.It is not clear whether regimens involving protease-modulating dressings increase the probability of pressure ulcer healing compared with saline gauze (risk ratio (RR) 1.65, 95% confidence interval (CI) 0.92 to 2.94) (moderate-certainty evidence: low risk of bias, downgraded for imprecision). This risk ratio of 1.65 corresponds to an absolute difference of 102 more people healed with protease modulating dressings per 1000 people treated than with saline gauze alone (95% CI 13 fewer to 302 more). It is unclear whether the following interventions increase the probability of healing compared with saline gauze (low-certainty evidence): collagenase ointment (RR 2.12, 95% CI 1.06 to 4.22); foam dressings (RR 1.52, 95% CI 1.03 to 2.26); basic wound contact dressings (RR 1.30, 95% CI 0.65 to 2.58) and polyvinylpyrrolidone plus zinc oxide (RR 1.31, 95% CI 0.37 to 4.62); the latter two interventions both had confidence intervals consistent with both a clinically important benefit and a clinically important harm, and the former two interventions each had high risk of bias as well as imprecision. AUTHORS' CONCLUSIONS: A network meta-analysis (NMA) of data from 39 studies (evaluating 21 dressings and topical agents for pressure ulcers) is sparse and the evidence is of low or very low certainty (due mainly to risk of bias and imprecision). Consequently we are unable to determine which dressings or topical agents are the most likely to heal pressure ulcers, and it is generally unclear whether the treatments examined are more effective than saline gauze.More research is needed to determine whether particular dressings or topical agents improve the probability of healing of pressure ulcers. The NMA is uninformative regarding which interventions might best be included in a large trial, and it may be that research is directed towards prevention, leaving clinicians to decide which treatment to use on the basis of wound symptoms, clinical experience, patient preference and cost.
[Mh] Termos MeSH primário: Bandagens
Fármacos Dermatológicos/uso terapêutico
Lesão por Pressão/terapia
Cicatrização
[Mh] Termos MeSH secundário: Alginatos/uso terapêutico
Curativos Hidrocoloides
Colagenases/uso terapêutico
Clara de Ovo
Géis/uso terapêutico
Ácido Glucurônico/uso terapêutico
Ácidos Hexurônicos/uso terapêutico
Seres Humanos
Metanálise em Rede
Pomadas/uso terapêutico
Excipientes Farmacêuticos/uso terapêutico
Fenitoína/uso terapêutico
Povidona/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Óxido de Zinco/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Alginates); 0 (Dermatologic Agents); 0 (Gels); 0 (Hexuronic Acids); 0 (Ointments); 0 (Pharmaceutic Aids); 6158TKW0C5 (Phenytoin); 8A5D83Q4RW (Glucuronic Acid); 8C3Z4148WZ (alginic acid); EC 3.4.24.- (Collagenases); FZ989GH94E (Povidone); SOI2LOH54Z (Zinc Oxide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011947.pub2


  2 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28220568
[Au] Autor:Grosch E; Mahler V
[Ad] Endereço:Department of Dermatology, University Hospital Erlangen, 91054 Erlangen, Germany.
[Ti] Título:Allergic contact dermatitis caused by a catheter system containing sodium metabisulfite.
[So] Source:Contact Dermatitis;76(3):186-187, 2017 Mar.
[Is] ISSN:1600-0536
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Cateteres/efeitos adversos
Dermatite Alérgica de Contato/etiologia
Excipientes Farmacêuticos/efeitos adversos
Sulfitos/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Cateterismo/instrumentação
Dermatite Alérgica de Contato/diagnóstico
Feminino
Seres Humanos
Testes do Emplastro
Excipientes Farmacêuticos/administração & dosagem
Sulfitos/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutic Aids); 0 (Sulfites); 4VON5FNS3C (sodium metabisulfite)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.1111/cod.12675


  3 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28167295
[Au] Autor:Poller B; Strachan C; Broadbent R; Walker GF
[Ad] Endereço:School of Pharmacy, University of Otago, Dunedin, New Zealand.
[Ti] Título:A minitablet formulation made from electrospun nanofibers.
[So] Source:Eur J Pharm Biopharm;114:213-220, 2017 May.
[Is] ISSN:1873-3441
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to evaluate electrospun drug loaded nanofibers as a new matrix for minitablets. Prednisone, a poorly water-soluble drug, was loaded into povidone (polyvinylpyrrolidone, PVP) nanofibers using the process of electrospinning. The drug-loaded nanofiber mat was compressed into minitablets with a 2mm diameter and a height of 2.63±0.04mm. SEM analysis of the minitablet identified a nano-web structure with a nanofiber diameter in the range of 400-500nm. The minitablets met the requirements of the US Pharmacopeia with respect to content uniformity and friability. DSC and XRPD analysis of the minitablet indicated that the drug-polymer mixture was a one-phase amorphous system. XRPD analysis of the drug loaded nanofiber mat after 10-months of storage at ambient temperature showed no evidence of recrystallization of the drug. Solubility and dissolution properties of the drug formulated into a nanofiber mat and minitablet were evaluated. These results show that electrospun nanofibers may provide a useful matrix for the further development of minitablets.
[Mh] Termos MeSH primário: Nanofibras/química
Comprimidos/química
[Mh] Termos MeSH secundário: Varredura Diferencial de Calorimetria
Composição de Medicamentos
Tamanho da Partícula
Excipientes Farmacêuticos
Povidona/química
Prednisona/administração & dosagem
Prednisona/farmacocinética
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutic Aids); 0 (Tablets); FZ989GH94E (Povidone); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE


  4 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28093380
[Au] Autor:Dyer O
[Ad] Endereço:Montreal.
[Ti] Título:Cleveland Clinic to re-evaluate its Wellness Institute after director questions vaccines.
[So] Source:BMJ;356:j253, 2017 Jan 16.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Centros Médicos Acadêmicos/normas
Academias de Ginástica/normas
Excipientes Farmacêuticos/efeitos adversos
Conservantes Farmacêuticos/efeitos adversos
Vacinas/efeitos adversos
[Mh] Termos MeSH secundário: Blogging
Seres Humanos
Ohio
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Pharmaceutic Aids); 0 (Preservatives, Pharmaceutical); 0 (Vaccines)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170118
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j253


  5 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28055127
[Au] Autor:Hernandes C; Pina ES; Taleb-Contini SH; Bertoni BW; Cestari IM; Espanha LG; Varanda EA; Camilo KF; Martinez EZ; França SC; Pereira AM
[Ad] Endereço:Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
[Ti] Título:Lippia origanoides essential oil: an efficient and safe alternative to preserve food, cosmetic and pharmaceutical products.
[So] Source:J Appl Microbiol;122(4):900-910, 2017 Apr.
[Is] ISSN:1365-2672
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: The aim of this work was to evaluate the efficacy and safety of Lippia origanoides essential oil as a preservative in industrial products. METHODS AND RESULTS: The composition, antimicrobial activity, mutagenic and toxic potential of L. origanoides were determined. Then, the effect of essential oil as a preservative in food, cosmetics and pharmaceutical products was evaluated. The essential oil of L. origanoides consisted mainly of oxygenated monoterpenes (38·13%); 26·28% corresponded to the compound carvacrol. At concentrations ranging from 0·312 to 1·25 µl ml and in association with polysorbate 80, the essential oil of L. origanoides inhibited the growth of all the tested micro-organisms. The medium lethal dose in mice was 3·5 g kg , which categorizes it as nontoxic according to the European Union criteria, and negative results in the Ames test indicated that this oil was not mutagenic. In combination with polysorbate 80, the essential oil exerted preservative action on orange juice, cosmetic and pharmaceutical compositions, especially in the case of aqueous-based products. CONCLUSIONS: Lippia origanoides essential oil is an effective and safe preservative for orange juice, pharmaceutical and cosmetic products. SIGNIFICANCE AND IMPACT OF THE STUDY: This study allowed for the complete understanding of the antimicrobial action and toxicological potential of L. origanoides essential oil. These results facilitate the development of a preservative system based on L. origanoides essential oil.
[Mh] Termos MeSH primário: Cosméticos
Conservantes de Alimentos/farmacologia
Lippia/química
Óleos Voláteis/farmacologia
Conservantes Farmacêuticos/farmacologia
[Mh] Termos MeSH secundário: Animais
Anti-Infecciosos/química
Anti-Infecciosos/farmacologia
Conservantes de Alimentos/química
Conservantes de Alimentos/toxicidade
Camundongos
Monoterpenos/química
Óleos Voláteis/química
Óleos Voláteis/toxicidade
Excipientes Farmacêuticos/química
Excipientes Farmacêuticos/farmacologia
Excipientes Farmacêuticos/toxicidade
Óleos Vegetais/química
Óleos Vegetais/farmacologia
Óleos Vegetais/toxicidade
Conservantes Farmacêuticos/química
Conservantes Farmacêuticos/toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Cosmetics); 0 (Food Preservatives); 0 (Monoterpenes); 0 (Oils, Volatile); 0 (Pharmaceutic Aids); 0 (Plant Oils); 0 (Preservatives, Pharmaceutical); 9B1J4V995Q (carvacrol)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170106
[St] Status:MEDLINE
[do] DOI:10.1111/jam.13398


  6 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27346557
[Au] Autor:Borges AF; Silva C; Coelho JF; Simões S
[Ad] Endereço:a Bluepharma, Indústria Farmacêutica , S.A , Portugal.
[Ti] Título:Outlining critical quality attributes (CQAs) as guidance for the development of orodispersible films.
[So] Source:Pharm Dev Technol;22(2):237-245, 2017 Mar.
[Is] ISSN:1097-9867
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Orodispersible films have gained increasing relevance as a novel dosage form. Associated to their particular processing and multicomponent composition, there are a vast number of reasons to establish helpful development guidance, gathering simultaneously the recent pharmaceutical regulatory trends. OBJECTIVE: This study aimed characterize marketed orodispersible films in order to provide essential information about a clear definition of product critical quality attributes (CQAs). MATERIALS AND METHODS: Several commercial orodispersible films were evaluated in terms of thickness, residual water content, disintegration time and mechanical and thermal properties. RESULTS: The orodispersible films exhibit a broad range of thickness [40-140 µm], probably associated with the height gap used on the cast of orodispersible films production. The majority of orodispersible films dissolved within [32-105s]. In general, a broad range of values were found for all the properties studied, residual water content [2.91-9.75%], Young's Modulus [51.25-1827 Mpa], tensile strength [1.47-33.91 Mpa] and tensile strain [0.32-38.2%]. DISCUSSION AND CONCLUSIONS: Despite the orodispersible films' complex composition, it was possible to establish correlations about the impact of the main excipients on the final product characteristics. Acceptable values for the CQAs were also defined, working as acceptance criteria for the development of new oral film formulations.
[Mh] Termos MeSH primário: Formas de Dosagem
Sistemas de Liberação de Medicamentos/métodos
Excipientes Farmacêuticos/química
[Mh] Termos MeSH secundário: Administração Oral
Módulo de Elasticidade
Preparações Farmacêuticas/administração & dosagem
Solubilidade
Resistência à Tração
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dosage Forms); 0 (Pharmaceutic Aids); 0 (Pharmaceutical Preparations); 059QF0KO0R (Water)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170315
[Lr] Data última revisão:
170315
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160628
[St] Status:MEDLINE
[do] DOI:10.1080/10837450.2016.1199567


  7 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26401959
[Au] Autor:Vraníková B; Gajdziok J; Dolezel P
[Ad] Endereço:a Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
[Ti] Título:The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin.
[So] Source:Pharm Dev Technol;22(2):138-147, 2017 Mar.
[Is] ISSN:1097-9867
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. OBJECTIVE: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon® CL-F, Vivasol® and Explotab®). MATERIALS AND METHODS: LSS were prepared by spraying rosuvastatin solution onto Neusilin® US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. RESULTS AND DISCUSSION: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab® showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon® CL-F (≥2.5% w/w). Also tablets with Vivasol® (2.5-4.0% w/w) showed fast disintegration and complete drug release. CONCLUSION: Kollidon® CL-F and Vivasol® in concentration ≥2.5% are suitable superdisintegrants for LSS with enhanced release of drug.
[Mh] Termos MeSH primário: Compostos de Alumínio/química
Anticolesterolemiantes/administração & dosagem
Compostos de Magnésio/química
Excipientes Farmacêuticos/química
Povidona/química
Rosuvastatina Cálcica/administração & dosagem
Silicatos/química
Amido/análogos & derivados
[Mh] Termos MeSH secundário: Anticolesterolemiantes/química
Composição de Medicamentos
Liberação Controlada de Fármacos
Rosuvastatina Cálcica/química
Solubilidade
Amido/química
Comprimidos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aluminum Compounds); 0 (Anticholesteremic Agents); 0 (Magnesium Compounds); 0 (Pharmaceutic Aids); 0 (Silicates); 0 (Tablets); 6M3P64V0NC (aluminum magnesium silicate); 83MVU38M7Q (Rosuvastatin Calcium); 9005-25-8 (Starch); 9063-38-1 (sodium starch glycolate); FZ989GH94E (Povidone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150925
[St] Status:MEDLINE
[do] DOI:10.3109/10837450.2015.1089900


  8 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27518458
[Au] Autor:Sadeghi F; Ashofteh M; Homayouni A; Abbaspour M; Nokhodchi A; Garekani HA
[Ad] Endereço:Targeted Drug Delivery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
[Ti] Título:Antisolvent precipitation technique: A very promising approach to crystallize curcumin in presence of polyvinyl pyrrolidon for solubility and dissolution enhancement.
[So] Source:Colloids Surf B Biointerfaces;147:258-264, 2016 Nov 01.
[Is] ISSN:1873-4367
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Curcumin with a vast number of pharmacological activities is a poorly water soluble drug which its oral bioavailability is profoundly limited by its dissolution or solubility in GI tract. Curcumin could be a good anticancer drug if its solubility could be increased. Therefore, the aim of the present study was to increase the dissolution rate of curcumin by employing antisolvent crystallization technique and to investigate the effect of polyvinyl pyrrolidone K30 (PVP) as colloidal particles in crystallization medium on resultant particles. Curcumin was crystalized in the presence of different amounts of PVP by antisolvent crystallization method and their physical mixtures were prepared for comparison purposes. The samples were characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD) and Fourier transform infrared spectroscopy (FT-IR). The solubility and dissolution of the treated and untreated curcumin were also determined. Antisolvent crystallization of curcumin led to the formation of particles with no definite geometric shape. It was interesting to note that the DSC and XRPD studies indicated the formation of a new polymorph and less crystallinity for particles crystallized in the absence of PVP. However, the crystallized curcumin in the presence of PVP was completely amorphous. All crystalized curcumin samples showed much higher dissolution rate compared to untreated curcumin. The amount of curcumin dissolved within 10 for treated curcumin in the presence of PVP (1:1 curcumin:PVP) was 7 times higher than untreated curcumin and this enhancement in the dissolution for curcumin samples crystallized in the absence of PVP was around 5 times. Overall' the results of this study showed that antisolvent crystallization method in the absence or presence of small amounts of PVP is very efficient in increasing the dissolution rate of curcumin to achieve better efficiency for curcumin.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/química
Cristalização/métodos
Curcumina/química
Povidona/química
Pós/química
[Mh] Termos MeSH secundário: Varredura Diferencial de Calorimetria
Química Farmacêutica
Estabilidade de Medicamentos
Microscopia Eletrônica de Varredura
Excipientes Farmacêuticos/química
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Pharmaceutic Aids); 0 (Powders); FZ989GH94E (Povidone); IT942ZTH98 (Curcumin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160813
[St] Status:MEDLINE


  9 / 2120 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27301710
[Au] Autor:Ito I; Ito A; Unezaki S
[Ad] Endereço:Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
[Ti] Título:Preparation of an oral acetaminophen film that is expected to improve medication administration: Effect of polyvinylpyrrolidone on physical properties of the film.
[So] Source:Drug Discov Ther;10(3):156-62, 2016.
[Is] ISSN:1881-7831
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:This study investigated the effect of polyvinylpyrrolidone (PVP) on a film containing carboxymethyl cellulose sodium (CMC) as a matrix to improve surface roughness caused by drug recrystallization. Acetaminophen (AA) was used as the model drug. Recrystallization is a problem encountered during the preparation of films that contain high drug doses, making them difficult to take. A film that does not disintegrate for clinical applications requires a smooth surface, moderate strength and elasticity, and a low level of adhesiveness to facilitate taking of the medication. Addition of PVP to the film formulation made the surface significantly smoother, and it was independent of the compounding method. Smooth films were obtained when the CMC concentration was kept constant and the amount of PVP was increased, but it also increased the adhesiveness and strength, and decreased the elasticity of the films. When high polymer concentration was kept constant and the ratio of CMC and PVP was varied, the films with smaller amounts of PVP tended to have a smoother surface and less adhesiveness. However, when the amount of PVP was reduced, the film strength increased and elasticity decreased. The amount of PVP had a negligible effect on drug dissolution behavior, making it useful for preparation of the AA film. However, it is necessary to determine the compounding method and the PVP load considering the adhesiveness, strength, and elasticity of the films.
[Mh] Termos MeSH primário: Acetaminofen/administração & dosagem
Acetaminofen/química
Analgésicos não Entorpecentes/administração & dosagem
Analgésicos não Entorpecentes/química
Povidona/química
[Mh] Termos MeSH secundário: Adesividade
Carboximetilcelulose Sódica
Cristalização
Composição de Medicamentos
Elasticidade
Excipientes Farmacêuticos
Solubilidade
Propriedades de Superfície
Comprimidos
Resistência à Tração
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Pharmaceutic Aids); 0 (Tablets); 362O9ITL9D (Acetaminophen); FZ989GH94E (Povidone); K679OBS311 (Carboxymethylcellulose Sodium)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160616
[St] Status:MEDLINE
[do] DOI:10.5582/ddt.2016.01034


  10 / 2120 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27272371
[Au] Autor:Kaur P; Bergrem A; Gerlyng P; Reims HM; Leh S; Valeur J
[Ad] Endereço:Avdeling for patologi Klinikk for medisin Lovisenberg Diakonale Sykehus * Nåværende arbeidssted: P. Kaur, Avdeling for blodsykdommer, Oslo universitetssykehus, Rikshospitalet.
[Ti] Título:A methadone user with anaemia, skeletal pain and altered appearance.
[Ti] Título:En metadonbruker med anemi, skjelettsmerter og endret utseende..
[So] Source:Tidsskr Nor Laegeforen;136(10):925-9, 2016 Jun.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:eng; nor
[Mh] Termos MeSH primário: Excipientes Farmacêuticos/efeitos adversos
Povidona/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Anemia/induzido quimicamente
Feminino
Seres Humanos
Metadona/administração & dosagem
Dor Musculoesquelética/induzido quimicamente
Tratamento de Substituição de Opiáceos/efeitos adversos
Abuso de Substâncias por Via Intravenosa/complicações
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Pharmaceutic Aids); FZ989GH94E (Povidone); UC6VBE7V1Z (Methadone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.15.0692



página 1 de 212 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde